GITNUXREPORT 2025

Eye Cancer Statistics

Eye cancer is rare; early detection improves survival and treatment outcomes significantly.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

The most common presenting symptom of ocular melanoma is a visual field change or visual disturbance

Statistic 2

The use of fine-needle aspiration biopsy can aid in diagnosing eye tumors with accuracy exceeding 90%

Statistic 3

There is no standardized screening program for early detection of eye cancers in the general population

Statistic 4

Advances in diagnostic imaging like ultrasound, MRI, and OCT have improved early detection rates of eye tumors

Statistic 5

Marrow cytokine profiles in patients with ocular cancer differ significantly from healthy controls, indicating immune involvement

Statistic 6

The average delay from initial symptoms to diagnosis of eye cancer can range from weeks to months, impacting prognosis

Statistic 7

Advanced imaging techniques like PET scans are being studied for detection of metastatic spread in ocular melanoma, with early promising results

Statistic 8

Ocular melanoma metastatic spread is most commonly detected through liver imaging techniques, emphasizing the need for regular surveillance in high-risk patients

Statistic 9

Eye cancers are often misdiagnosed initially due to their rarity and resemblance to benign eye conditions, highlighting the need for specialized ophthalmic assessment

Statistic 10

The global incidence of ocular melanoma is approximately 5-6 cases per million people annually

Statistic 11

Uveal melanoma accounts for about 85-90% of all primary eye cancers

Statistic 12

Conjunctival melanoma is a rare form of eye cancer, with an estimated incidence of 0.2 cases per million annually

Statistic 13

Age is a significant risk factor; most ocular melanomas occur in individuals over age 50

Statistic 14

Iris melanoma accounts for about 4% of uveal melanomas

Statistic 15

Male patients have a slightly higher incidence of ocular melanoma than females

Statistic 16

History of sunlight exposure may increase risk for conjunctival melanoma

Statistic 17

Choroidal melanoma is the most common primary malignant intraocular tumor in adults

Statistic 18

The median age at diagnosis for ocular melanoma is approximately 60 years

Statistic 19

Eye cancer is relatively rare, accounting for about 3% of all systemic cancers

Statistic 20

Rare hereditary conditions such as retinoblastoma significantly increase the risk of eye cancer in children

Statistic 21

Retinoblastoma occurs in approximately 1 in every 15,000 to 20,000 live births

Statistic 22

Intraocular lymphoma constitutes about 1-2% of non-Hodgkin lymphomas

Statistic 23

The primary risk factors for ocular melanoma include fair skin, blue or green eyes, and light-colored eye pigmentation

Statistic 24

Approximately 10-15% of patients with uveal melanoma have a germline mutation in the BAP1 gene, linked to higher metastatic risk

Statistic 25

Eye cancer accounts for about 3% of all head and neck cancers, but is much rarer overall

Statistic 26

The incidence of conjunctival melanoma is higher in regions with increased UV exposure, such as Australia and parts of the Mediterranean

Statistic 27

The prevalence of ocular surface tumors has increased over recent decades, possibly related to UV exposure and other environmental factors

Statistic 28

The risk of eye cancer increases in immunocompromised individuals, such as those with HIV/AIDS, due to decreased immune surveillance

Statistic 29

The global burden of eye cancers is expected to rise with aging populations and increased UV exposure, projecting a significant public health challenge

Statistic 30

Approximately 30% of conjunctival melanomas originate from pre-existing nevi, indicating the importance of monitoring pigmented eye lesions

Statistic 31

Incidence of uveal melanoma varies geographically, being more common in Caucasians and rare in Asians and Africans

Statistic 32

The global incidence of retinoblastoma varies significantly, with higher rates reported in low- and middle-income countries due to limited early detection

Statistic 33

Approximately 50% of patients diagnosed with intraocular melanoma will develop metastasis within 10 years

Statistic 34

The five-year survival rate for localized eye melanoma is around 85%

Statistic 35

The prognosis of intraocular melanoma heavily relies on tumor size and location

Statistic 36

The recurrence rate after eye tumor treatment varies but can be as high as 15%, depending on the type and stage of cancer

Statistic 37

The rare but aggressive type of eyelid melanoma has a five-year survival rate of approximately 25%

Statistic 38

Ocular surface squamous neoplasia (OSSN) can progress to invasive carcinoma if untreated

Statistic 39

The overall survival rate for conjunctival melanoma is approximately 70%, but decreases significantly with regional metastasis

Statistic 40

The median time from diagnosis to metastasis for ocular melanoma is around 5 years, but can vary widely

Statistic 41

Ocular melanoma often spreads to the Liver as the most common metastatic site, accounting for 90% of metastases

Statistic 42

The prognosis for metastatic eye melanoma is poor, with a median survival of less than 12 months after detection of metastasis

Statistic 43

Rates of metastasis vary by tumor size, with larger tumors (>10mm thickness) having a higher likelihood of spreading

Statistic 44

The expression of HLA class I molecules on tumor cells impacts immune response and prognosis in ocular melanoma

Statistic 45

The discovery of chromosomal aberrations such as monosomy 3 is associated with worse prognosis in uveal melanoma

Statistic 46

Tumor thickness over 2mm is associated with increased risk of metastatic spread in uveal melanoma

Statistic 47

The survival rate for children with retinoblastoma is over 95% with early detection and treatment

Statistic 48

The presence of epithelioid cells in uveal melanoma correlates with a higher likelihood of metastasis and poorer prognosis

Statistic 49

Tumor localization close to important structures like the optic nerve can complicate surgical treatment and impact prognosis

Statistic 50

The annual cost of treating eye cancers in the United States exceeds $300 million

Statistic 51

The primary treatment for intraocular melanoma often involves radiation therapy, such as brachytherapy

Statistic 52

Immunotherapy is emerging as a promising treatment option for certain types of eye cancer

Statistic 53

Enucleation (removal of the eye) remains a common treatment for large intraocular tumors, especially when vision preservation isn't feasible

Statistic 54

The use of photodynamic therapy (PDT) shows promise in treating some superficial eye tumors, with minimal side effects

Statistic 55

There are ongoing clinical trials exploring gene therapy approaches for intraocular melanoma, aiming to target tumor growth at the molecular level

Statistic 56

The use of targeted therapy drugs like MEK inhibitors is currently under investigation for treating metastatic uveal melanoma, sources include ongoing clinical trials

Statistic 57

Recent advancements in molecular profiling of eye tumors have led to more personalized treatment plans, improving prognosis

Slide 1 of 57

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

The global incidence of ocular melanoma is approximately 5-6 cases per million people annually
Uveal melanoma accounts for about 85-90% of all primary eye cancers
Conjunctival melanoma is a rare form of eye cancer, with an estimated incidence of 0.2 cases per million annually
Approximately 50% of patients diagnosed with intraocular melanoma will develop metastasis within 10 years
The five-year survival rate for localized eye melanoma is around 85%
The most common presenting symptom of ocular melanoma is a visual field change or visual disturbance
Age is a significant risk factor; most ocular melanomas occur in individuals over age 50
Iris melanoma accounts for about 4% of uveal melanomas
Male patients have a slightly higher incidence of ocular melanoma than females
History of sunlight exposure may increase risk for conjunctival melanoma
The annual cost of treating eye cancers in the United States exceeds $300 million
Choroidal melanoma is the most common primary malignant intraocular tumor in adults
The median age at diagnosis for ocular melanoma is approximately 60 years

Did you know that while eye cancer remains rare, its aggressive forms like ocular melanoma pose significant health risks—with a survival rate dropping to just 25% in the most dangerous cases—highlighting the critical importance of early detection and advances in treatment?

Diagnosis and Detection

The most common presenting symptom of ocular melanoma is a visual field change or visual disturbance
The use of fine-needle aspiration biopsy can aid in diagnosing eye tumors with accuracy exceeding 90%
There is no standardized screening program for early detection of eye cancers in the general population
Advances in diagnostic imaging like ultrasound, MRI, and OCT have improved early detection rates of eye tumors
Marrow cytokine profiles in patients with ocular cancer differ significantly from healthy controls, indicating immune involvement
The average delay from initial symptoms to diagnosis of eye cancer can range from weeks to months, impacting prognosis
Advanced imaging techniques like PET scans are being studied for detection of metastatic spread in ocular melanoma, with early promising results
Ocular melanoma metastatic spread is most commonly detected through liver imaging techniques, emphasizing the need for regular surveillance in high-risk patients
Eye cancers are often misdiagnosed initially due to their rarity and resemblance to benign eye conditions, highlighting the need for specialized ophthalmic assessment

Diagnosis and Detection Interpretation

Despite advances in imaging and diagnostic tools, early detection of ocular melanoma remains hampered by the lack of standardized screening and delayed diagnoses, underscoring the need for heightened awareness and specialized assessments, especially given its subtle symptoms and potential for metastatic spread.

Epidemiology and Risk Factors

The global incidence of ocular melanoma is approximately 5-6 cases per million people annually
Uveal melanoma accounts for about 85-90% of all primary eye cancers
Conjunctival melanoma is a rare form of eye cancer, with an estimated incidence of 0.2 cases per million annually
Age is a significant risk factor; most ocular melanomas occur in individuals over age 50
Iris melanoma accounts for about 4% of uveal melanomas
Male patients have a slightly higher incidence of ocular melanoma than females
History of sunlight exposure may increase risk for conjunctival melanoma
Choroidal melanoma is the most common primary malignant intraocular tumor in adults
The median age at diagnosis for ocular melanoma is approximately 60 years
Eye cancer is relatively rare, accounting for about 3% of all systemic cancers
Rare hereditary conditions such as retinoblastoma significantly increase the risk of eye cancer in children
Retinoblastoma occurs in approximately 1 in every 15,000 to 20,000 live births
Intraocular lymphoma constitutes about 1-2% of non-Hodgkin lymphomas
The primary risk factors for ocular melanoma include fair skin, blue or green eyes, and light-colored eye pigmentation
Approximately 10-15% of patients with uveal melanoma have a germline mutation in the BAP1 gene, linked to higher metastatic risk
Eye cancer accounts for about 3% of all head and neck cancers, but is much rarer overall
The incidence of conjunctival melanoma is higher in regions with increased UV exposure, such as Australia and parts of the Mediterranean
The prevalence of ocular surface tumors has increased over recent decades, possibly related to UV exposure and other environmental factors
The risk of eye cancer increases in immunocompromised individuals, such as those with HIV/AIDS, due to decreased immune surveillance
The global burden of eye cancers is expected to rise with aging populations and increased UV exposure, projecting a significant public health challenge
Approximately 30% of conjunctival melanomas originate from pre-existing nevi, indicating the importance of monitoring pigmented eye lesions

Epidemiology and Risk Factors Interpretation

While ocular melanoma remains a rare disease affecting roughly 6 in a million annually and predominantly strikes those over 50 with fair features and sun exposure, its subtle prevalence underscores the need for vigilant eye health as the aging population and environmental factors continue to elevate the silent threat of eye cancer on the global stage.

Geographical and Demographic Variations

Incidence of uveal melanoma varies geographically, being more common in Caucasians and rare in Asians and Africans
The global incidence of retinoblastoma varies significantly, with higher rates reported in low- and middle-income countries due to limited early detection

Geographical and Demographic Variations Interpretation

These eye cancer statistics highlight a paradox: while uveal melanoma's racial predilections expose racial vulnerabilities, the uneven global distribution of retinoblastoma underscores how disparities in healthcare access can turn deadly tumors into preventable tragedies.

Prognosis and Survival Rates

Approximately 50% of patients diagnosed with intraocular melanoma will develop metastasis within 10 years
The five-year survival rate for localized eye melanoma is around 85%
The prognosis of intraocular melanoma heavily relies on tumor size and location
The recurrence rate after eye tumor treatment varies but can be as high as 15%, depending on the type and stage of cancer
The rare but aggressive type of eyelid melanoma has a five-year survival rate of approximately 25%
Ocular surface squamous neoplasia (OSSN) can progress to invasive carcinoma if untreated
The overall survival rate for conjunctival melanoma is approximately 70%, but decreases significantly with regional metastasis
The median time from diagnosis to metastasis for ocular melanoma is around 5 years, but can vary widely
Ocular melanoma often spreads to the Liver as the most common metastatic site, accounting for 90% of metastases
The prognosis for metastatic eye melanoma is poor, with a median survival of less than 12 months after detection of metastasis
Rates of metastasis vary by tumor size, with larger tumors (>10mm thickness) having a higher likelihood of spreading
The expression of HLA class I molecules on tumor cells impacts immune response and prognosis in ocular melanoma
The discovery of chromosomal aberrations such as monosomy 3 is associated with worse prognosis in uveal melanoma
Tumor thickness over 2mm is associated with increased risk of metastatic spread in uveal melanoma
The survival rate for children with retinoblastoma is over 95% with early detection and treatment
The presence of epithelioid cells in uveal melanoma correlates with a higher likelihood of metastasis and poorer prognosis
Tumor localization close to important structures like the optic nerve can complicate surgical treatment and impact prognosis

Prognosis and Survival Rates Interpretation

While localized eye melanomas boast a promising 85% five-year survival rate, the shadow of metastasis looms large—with half of intraocular melanoma patients facing a decade-long battle, primarily targeting the liver, and when it spreads, prognosis dims sharply, proving that in the eye, size and location aren't just details—they're the differences between sight and silence.

Treatment and Management

The annual cost of treating eye cancers in the United States exceeds $300 million
The primary treatment for intraocular melanoma often involves radiation therapy, such as brachytherapy
Immunotherapy is emerging as a promising treatment option for certain types of eye cancer
Enucleation (removal of the eye) remains a common treatment for large intraocular tumors, especially when vision preservation isn't feasible
The use of photodynamic therapy (PDT) shows promise in treating some superficial eye tumors, with minimal side effects
There are ongoing clinical trials exploring gene therapy approaches for intraocular melanoma, aiming to target tumor growth at the molecular level
The use of targeted therapy drugs like MEK inhibitors is currently under investigation for treating metastatic uveal melanoma, sources include ongoing clinical trials
Recent advancements in molecular profiling of eye tumors have led to more personalized treatment plans, improving prognosis

Treatment and Management Interpretation

With over $300 million annually spent on eye cancer treatment and advances from radiation therapy to gene targeting, the burgeoning field aims to preserve sight and life alike—though sometimes, the best cure remains removing the eye itself.